IWM
LCTX icon

IHT Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

IHT Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9,343
Closed -$21K – 940
2018
Q1 		$21K Hold
9,343
– – 0.01% 957
2017
Q4 		$22K Buy
9,343
+1,048
+13% +$2.29K 0.01% 961
2017
Q3 		$21K Hold
8,295
– – 0.01% 765
2017
Q2 		$0 Buy
8,295
+675
+9% +$1.89K ﹤0.01% 1435
2017
Q1 		$22K Buy
7,620
+5,334
+233% +$15.1K 0.01% 634
2016
Q4 		$7K Buy
+2,286
New +$7.02K 0.01% 870

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

IHT Wealth Management's LCTX Position: Q2 2018 in Review

IHT Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2018, closing a stake of 9,343 shares — an estimated $21K sold.

IHT Wealth Management first reported a position in LCTX in Q4 2016 and held it in 6 quarters. The position peaked at $22K in Q4 2017. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2018.

  • IHT Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q2 2018 after selling out during the quarter.
  • IHT Wealth Management sold 9,343 Lineage Cell Therapeutics shares in Q2 2018, an estimated $21K.
  • IHT Wealth Management first reported a position in Lineage Cell Therapeutics in Q4 2016 and held it in 6 quarters.
  • IHT Wealth Management's Lineage Cell Therapeutics position peaked at $22K in Q4 2017.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.